UK Markets open in 2 hrs 7 mins

Graphite Bio, Inc. (GRPH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.0700+0.0600 (+1.99%)
At close: 04:00PM EDT
3.1500 +0.08 (+2.61%)
After hours: 06:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.0100
Open2.9400
Bid0.0000 x 800
Ask0.0000 x 1400
Day's range2.9000 - 3.1100
52-week range2.0700 - 17.1300
Volume488,279
Avg. volume313,206
Market cap178.303M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-7.0540
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.50
  • Business Wire

    Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., September 06, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022, at 12:55 pm ET.

  • Business Wire

    Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results

    SOUTH SAN FRANCISCO, Calif., August 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today reported recent business progress and second quarter 2022 financial results.

  • Business Wire

    Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

    SOUTH SAN FRANCISCO, Calif., August 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that the first patient has been dosed with GPH101, now called nulabeglogene autogedtemcel (nula-cel), in the company’s Phase 1/2 CEDAR trial in people with sickle cell disease (SCD). Nula-cel is an investigational gene e